NCT05819294

Brief Summary

The goal of this study is to compare the diagnostic yield in terms of cellular content and biochemical characteristics of pre-aspiration agitated pleural fluid versus that of conventionally aspirated fluid in pleural infection patients. The hypothesis is that the agitated fluid would be more representative and thus may aid the diagnosis of non-infected exudative pleural effusions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2023

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

April 6, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 19, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

April 21, 2023

Status Verified

April 1, 2023

Enrollment Period

11 months

First QC Date

April 6, 2023

Last Update Submit

April 19, 2023

Conditions

Keywords

pleural effusionexudate

Outcome Measures

Primary Outcomes (3)

  • Diagnostic yield of the cytological analysis

    Percentage of samples with a positive cytological result among both aspiration techniques

    14 days

  • Diagnostic yield of the microbiolocal analysis (mycobacterial / fungal)

    Percentage of samples with a evidence of mycobacterial / fungal elements among both aspiration techniques

    14 days

  • Incidence of adverse events with pre-aspiration fluid agitation

    Percentage of patients with incidence of adverse events during or right after pre-aspiration fluid agitation including pneumothorax or significant pain or cough or oxygen desaturation

    14 days

Secondary Outcomes (5)

  • Protein level difference between both aspiration method

    results within 1 day of sampling

  • Lactate dehydrogenase (LDH) level difference between both aspiration method

    results within 1 day of sampling

  • Glusose level difference between both aspiration method

    results within 1 day of sampling

  • Neutrophilic count difference between both aspiration method

    results within 1 day of sampling

  • Lymphocytic count difference between both aspiration method

    results within 1 day of sampling

Study Arms (1)

Standard thoracentesis followed by pre-aspiration fluid agitation

EXPERIMENTAL

Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique

Procedure: Agitated Pleural Fluid Thoracentesis

Interventions

Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe

Standard thoracentesis followed by pre-aspiration fluid agitation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 years old
  • At least a moderate amount of pleural fluid collection (2 or more intercostal spaces on thoracic ultrasound)

You may not qualify if:

  • Minimal - mild pleural fluid deemed unsuitable for aspiration and agitation
  • Hemodynamic instability
  • Pleural infection based on clinical presentation, imaging or laboratory investigations and pleural fluid examination showing glucose \< 40 mg/dL or pH \<7.2 with lower respiratory infection, positive gram stain or bacterial culture or pus on aspiration

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chest Diseases Department, Alexandria University Faculty of Medicine

Alexandria, Egypt

Location

MeSH Terms

Conditions

Pleural Effusion

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Laboratory personnel responsible for the cytological and biochemical analysis will be blinded to the identity of the paired samples
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: All participants will undergo both thoracentesis techniques; the standard and the experimental pre-aspiration agitated fluid techniques
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

April 6, 2023

First Posted

April 19, 2023

Study Start

April 1, 2023

Primary Completion

March 1, 2024

Study Completion

April 1, 2024

Last Updated

April 21, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations